Zafirlukast CAS 107753-78-6： Effective Asthma Relief Solution Explained

2025-3-21

Productos

This article provides a comprehensive guide to Zafirlukast CAS 107753-78-6, an effective asthma relief solution. It covers various aspects such as product parameters, usage scenarios, case studies, solutions, expert guidance, and frequently asked questions. By the end of this guide, readers will have a clear understanding of how Zafirlukast can help alleviate asthma symptoms.

Resumen del producto

Zafirlukast CAS 107753-78-6 is a leukotriene receptor antagonist that effectively relieves asthma symptoms. This guide will delve into the details of this asthma relief solution, helping readers understand its benefits, usage, and how it can be incorporated into their asthma management plan.

Parámetros del producto

Table 1: Zafirlukast CAS 107753-78-6 Product Parameters

Parámetro	Valor
Nombre químico	Zafirlukast
Fórmula	C₂₀H₂₄N₄O₂
Peso molecular	356.44 g/mol
Apariencia	Polvo cristalino entre blanco y blanquecino

Escenarios de uso

Zafirlukast CAS 107753-78-6 is suitable for individuals suffering from asthma, particularly those with mild to moderate persistent asthma. It can be used as a standalone medication or in combination with other asthma treatments. Here are some common scenarios where Zafirlukast can be beneficial:

Moderate persistent asthma: Zafirlukast can help reduce the frequency and severity of asthma attacks in individuals with moderate persistent asthma.
Prevention of exercise-induced asthma: Zafirlukast can be taken before exercise to prevent asthma symptoms in individuals prone to exercise-induced asthma.
Management of allergic rhinitis: Zafirlukast can also be used to manage symptoms of allergic rhinitis, which is often associated with asthma.

Casos prácticos

Case Study 1: John, a 35-year-old with moderate persistent asthma, started taking Zafirlukast CAS 107753-78-6. After a few weeks, he noticed a significant reduction in the frequency of asthma attacks and a decrease in the use of his rescue inhaler.

Case Study 2: Sarah, a 45-year-old with exercise-induced asthma, began using Zafirlukast CAS 107753-78-6 before her morning runs. She experienced fewer asthma symptoms and was able to continue her exercise routine without interruption.

Soluciones

Zafirlukast CAS 107753-78-6 works by blocking the action of leukotrienes, which are inflammatory substances that can cause asthma symptoms. By inhibiting leukotriene activity, Zafirlukast helps to reduce airway inflammation and improve lung function. This makes it an effective asthma relief solution for individuals with mild to moderate persistent asthma.

Expert Guidance

It is essential to consult with a healthcare professional before starting Zafirlukast CAS 107753-78-6. They can assess your asthma condition and determine if Zafirlukast is the right asthma relief solution for you. Your healthcare provider will also guide you on the appropriate dosage and duration of treatment.

Preguntas frecuentes

Q: Can Zafirlukast CAS 107753-78-6 be used in children?
A: Yes, Zafirlukast CAS 107753-78-6 can be used in children aged 6 years and older, under the guidance of a healthcare professional.
Q: Can Zafirlukast CAS 107753-78-6 be taken with other asthma medications?
A: Yes, Zafirlukast CAS 107753-78-6 can be taken with other asthma medications, such as inhaled corticosteroids, as prescribed by a healthcare professional.
Q: Are there any side effects associated with Zafirlukast CAS 107753-78-6?
A: Like all medications, Zafirlukast CAS 107753-78-6 may cause side effects, although not everyone experiences them. Common side effects include headache, stomach pain, and dizziness. Consult with your healthcare provider if you experience any side effects.

Conclusión

Zafirlukast CAS 107753-78-6 is an effective asthma relief solution for individuals with mild to moderate persistent asthma. By understanding its product parameters, usage scenarios, case studies, solutions, expert guidance, and frequently asked questions, readers can make informed decisions about incorporating Zafirlukast into their asthma management plan.